Peptide-loaded nanoparticles and radionuclide imaging for individualized treatment of myocardial ischemia.

PURPOSE To determine whether chitosan hydrogel nanoparticles loaded with vascular endothelial growth factor (VEGF) peptides (81-91 fragments) capable of targeting the ischemic myocardium enhance angiogenesis and promote therapeutic effects and whether radionuclide image-guided dosage control is feasible. MATERIALS AND METHODS Experimental procedures and protocols were approved by the Institutional Animal Care and Use Committee. Rats (n = 32, eight per group) were subjected to myocardial ischemia (control group) and received chitosan hydrogel nanoparticles with VEGF165 proteins (chitosan VEGF) or VEGF81-91 peptides (chitosan peptides) via apical puncture. Ischemic hearts receiving chitosan without angiogenic factors served as the chitosan control. Myocardial perfusion was examined 7 days after surgery by using technetium 99m ((99m)Tc) tetrofosmin (37 MBq) autoradiography, and changes in vascular density with immunohistochemical staining were reviewed. Kruskal-Wallis test and Bonferroni corrected Mann-Whitney U test were used for multiple comparisons. Wilcoxon signed rank test was used to compare myocardial retention of (99m)Tc chitosan. RESULTS Thirty minutes of myocardial ischemia resulted in perfusion defects (median, 54%; interquartile range [IQR], 41%-62%). Chitosan VEGF decreased perfusion defect extent (median, 68%; IQR, 63%-73%; P = .006 vs control) and increased vascular density (median, 81 vessels per high-power field; IQR, 72-100; P = .009 vs control). Administration of chitosan peptides reduced the degree of perfusion defects (median, 66%; IQR, 62%-73%; P = .006 vs control) and increased vascular density (median, 82 vessels; IQR, 78-92; P = .006 vs control). The effects of chitosan peptides on perfusion and vascular density were comparable to those seen with chitosan VEGF proteins (P = .713 and P = .833, respectively). Chitosan radiolabeled with (99m)Tc was administered twice at reperfusion with a 1-hour interval to determine whether image-guided dosage control is feasible. The hearts initially retained 4.6% (IQR, 4.1%-5.0%) of (99m)Tc chitosan administered and 9.2% (IQR, 6.6%-12.7%; P = .068) with subsequent injection. CONCLUSION VEGF peptides have angiogenic potential and resulted in therapeutic effectiveness. Adjunct use of single photon emission computed tomography was also demonstrated for individualized treatment of myocardial ischemia by further tailoring the therapeutic dosing. Online supplemental material is available for this article.

[1]  Hong Yuan,et al.  Cellular uptake and cytotoxicity of shell crosslinked stearic acid-grafted chitosan oligosaccharide micelles encapsulating doxorubicin. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[2]  M. Simons,et al.  Growth factor-induced therapeutic angiogenesis in the heart: protein therapy. , 2005, Cardiovascular research.

[3]  R. Hendel,et al.  Myocardial perfusion imaging with 99mTc tetrofosmin. Comparison to 201Tl imaging and coronary angiography in a phase III multicenter trial. Tetrofosmin International Trial Study Group. , 1995, Circulation.

[4]  Wadih Arap,et al.  From combinatorial peptide selection to drug prototype (I): Targeting the vascular endothelial growth factor receptor pathway , 2010, Proceedings of the National Academy of Sciences.

[5]  Lorenzo Deveza,et al.  Therapeutic Angiogenesis for Treating Cardiovascular Diseases , 2012, Theranostics.

[6]  F. Sellke,et al.  Therapeutic angiogenesis in cardiology using protein formulations. , 2001, Cardiovascular research.

[7]  R. Hendel,et al.  Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. , 2001, American heart journal.

[8]  R. Hendel,et al.  Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. , 2000, Circulation.

[9]  X. Chen,et al.  Uptake of oleoyl-chitosan nanoparticles by A549 cells. , 2008, Nanomedicine : nanotechnology, biology, and medicine.

[10]  M. Garcia‐Fuentes,et al.  Chitosan-based drug nanocarriers: where do we stand? , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[11]  J. Pearlman,et al.  Vascular endothelial growth factor administration in chronic myocardial ischemia. , 1996, The American journal of physiology.

[12]  David J Mooney,et al.  Effects of VEGF temporal and spatial presentation on angiogenesis. , 2010, Biomaterials.

[13]  L. Morbidelli,et al.  Functional and pharmacological characterization of a VEGF mimetic peptide on reparative angiogenesis. , 2012, Biochemical pharmacology.

[14]  D. Mooney,et al.  Targeted delivery of nanoparticles to ischemic muscle for imaging and therapeutic angiogenesis. , 2011, Nano letters.

[15]  Petra Krystek,et al.  Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. , 2008, Biomaterials.

[16]  J. Leor,et al.  The promotion of myocardial repair by the sequential delivery of IGF-1 and HGF from an injectable alginate biomaterial in a model of acute myocardial infarction. , 2011, Biomaterials.

[17]  J L Cleland,et al.  Development of poly-(D,L-lactide--coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[18]  Kinam Park,et al.  Targeted drug delivery to tumors: myths, reality and possibility. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[19]  S. Epstein,et al.  Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. , 1994, Circulation.

[20]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  Larry Kedes,et al.  Washout of transplanted cells from the heart: a potential new hurdle for cell transplantation therapy. , 2005, Cardiovascular research.

[22]  A. D. de Vos,et al.  VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. , 1998, Structure.

[23]  M. Martín-Martínez,et al.  Parallel solid-phase synthesis of a small library of linear and hydrocarbon-bridged analogues of VEGF(81-91): potential biological tools for studying the VEGF/VEGFR-1 interaction. , 2011, Bioorganic & medicinal chemistry.

[24]  K. Christman,et al.  Biomaterials for the treatment of myocardial infarction: a 5-year update. , 2011, Journal of the American College of Cardiology.

[25]  S. Epstein,et al.  Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. , 1996, Circulation.

[26]  Brian H Annex,et al.  The VIVA Trial Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis , 2003 .

[27]  G. Dellgren,et al.  Angiogenic and cardiac functional effects of dual gene transfer of VEGF-A165 and PDGF-BB after myocardial infarction. , 2004, Biochemical and biophysical research communications.

[28]  M. Martín-Martínez,et al.  Disulfide and amide-bridged cyclic peptide analogues of the VEGF₈₁₋₉₁ fragment: synthesis, conformational analysis and biological evaluation. , 2011, Bioorganic & medicinal chemistry.

[29]  J. Isner,et al.  Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. , 1995, Circulation.

[30]  Brian H Annex,et al.  A target‐mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans , 2002, Clinical pharmacology and therapeutics.

[31]  L. Zentilin,et al.  Inducible adeno-associated virus vectors promote functional angiogenesis in adult organisms via regulated vascular endothelial growth factor expression. , 2009, Cardiovascular research.

[32]  R. Kloner,et al.  Improving regenerating potential of the heart after myocardial infarction: factor-based approach. , 2010, Life sciences.